Here are five notes:
1. The 52-week low is 5 percent below today’s share price of $12.83.
2. The company is currently valued at $535.56 million. However, If K2M achieves its $12.19 price target, the company will be worth $26.78 million less.
3. On Feb. 3, K2M shares fell 1.23 percent.
4. The company has declined 46.59 percent since June 30.
5. The shares have underperformed the S&P 500 by 39.07 percent.
More articles on devices:
Vergenix STR receives positive final trial results — 5 highlights
Zacks Investment Research upgrades Cytori Therapeutics stock — 5 insights
Episurf Medical’s μifidelity platform reaches 100 case milestone: 3 points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
